Evidence map›Paper›PMID 29242769›Full record

ArticleCurrent tropical medicine reports2017

Vaccines for the Prevention of Melioidosis and Glanders.

Monica M Johnson, Kristy M Ainslie

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current tropical medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Monica M JohnsonDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, USA.
Kristy M AinslieDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, USA.
University of North Carolina at Chapel Hill · US

Funding

Host Targeted Therapy for Drug Resistant Salmonella and Francisella infectionR01AI125147 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AINSLIE, KRISTY M, BLOUGH, BRUCE E · 2016 to 2020
$6.0M
Microparticle resiquimod for the treatment of visceral leishmaniasisR21AI123692 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI AINSLIE, KRISTY M · 2016 to 2017
$424k
Celecoxib Derivative: Host Cell-Directed Inhibitors of Intracellular PathogensR21AI102252 · NIAID · OHIO STATE UNIVERSITY · PI AINSLIE, KRISTY M · 2012 to 2013
$410k
NIAID NIH HHS R01 AI125147NIAID NIH HHS R21 AI102252NIAID NIH HHS R21 AI123692
6 · The paper itself

Abstract

purpose of reviewRECENT

findingsSeveral live attenuated and subunit vaccine formulations have been evaluated in animal studies, with no reports of significant long term survival after lethal challenge. SUMMARY: This review encompasses the most current vaccine strategies to prevent

Indexed as

Burkholderia malleiBurkholderia pseudomalleiglandersmelioidosisvaccines

Identifiers

PMID29242769
PMCPMC5724791
OpenAlexW2734586458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.